Lancet: ECMO is used for the treatment of patients with sepsis heart-source shock.

Clinical sepsis leads to a higher mortality rate in patients with myocardial disease combined with cardiopathic shock.
recently evaluated the effectiveness of venous-arterial intraostrophic membrane oxygenation (VA-ECMO) for sepsis-related heart-based shock.
study was conducted at five ECMO centers, with 82 adult infectious shock patients treated with VA-ECMO, 130 controlled patients not treated with VA-ECMO, and patients with severe cardiomyopathy disorders (heart index 3L/) min/m2 or less or left-room blood fractions (LVEF) 35% or less) and severe hemodynamic damage (Inotrope score is at least 75 sg/kg/min or blood lactic acid concentration at least 4mmol/L).
end of the study was a 90-day survival rate.
baseline, VA-ECMO patients had more severe cardiomyopathy disorders (average heart index: 1.5 vs. 2.2 L/min/m2, LVEF: 17% vs 27%), and more severe hemodynamic impairment (17% vs. 27%) Inotrope score: 279 vs. 145 sg/kg/min; Lactic acid concentration: 8.9 vs 6.5 mmol/L) and more severe organ failure symptoms (Sequentia organ failure assessment score: 17 vs 13).
VA-ECMO intervention, the patient's 90-day survival rate increased significantly (60 vs. 25%, with a fatality ratio of 0.54).
, ECMO interventions can still improve patient survival (51% vs. 14%, risk of death 0.57).
ECMO intervention can improve the removal rate of lactic acid and pacrysamine in patients.
36 of the 49 patients who survived ECMO were assessed for health-related quality of life a year later.
that ECMO can help improve survival in patients with sepsis heart-source shock.
.